PREVENAR 13 (pneumococcal polysaccharide conjugate vaccine, 13 valent-adsorbed) 0.5 mL suspension for injection. PREVENAR 13 is a medicine for the immunisation against disease caused by Streptococcus pneumoniae strains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children aged more than 6 weeks of age. PREVENAR 13 does not provide 100% protection against vaccine strains or protect against non-vaccine strains. PREVENAR 13 is a fully funded prescription medicine for children up to 5 years of age, as part of the National Immunisation Schedule, and for older children and adults meeting certain high-risk criteria (your doctor will advise if you or your child meet these criteria). For those not meeting these criteria, PREVENAR 13 is an unfunded medicine – a pharmacy charge may apply and a normal doctor’s fee applies. PREVENAR 13 has risks and benefits. Use strictly as directed. If you have side effects, see your doctor, pharmacist or healthcare professional. Consult your doctor to see if PREVENAR 13 is right for you or your child. Contains: 30.8 micrograms of pneumococcal purified capsular polysaccharides. Further information on PREVENAR 13 and the Consumer Medicine Information is available from www.medsafe.govt.nz or Pfizer New Zealand Limited, Auckland, www.pfizer.co.nz. Ph. 0800 736 363.V10715. Immunisation schedules for PREVENAR 13 should be based on official recommendations. Because infections of the middle ear and lung can be caused by bugs other than the strains of the pneumococcal bug in the vaccine, protection against all middle ear and lung infections is expected to be lower than for invasive disease caused by the pneumococcal bug. Prevenar 13® is a Registered Trademark of Pfizer New Zealand Limited, Level 1, Suite 1.4, Building B, 8 Nugent Street, Grafton, Auckland 1023. DA1534SW. TAPS CH4145. BCG2-H PRE0308. PP-PNP-NZL-0041. 08/2015.